60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Disc Medicine, Inc. (NASDAQ:IRON) Chief Operating Officer Yu Jonathan Yen-Wen, on November 11, 2025, sold 30,000 shares of common stock for a total of $2,540,922. The sales were executed in multiple transactions with prices ranging from $83.1453 to $85.9129. The biotech company’s stock, currently trading at $87.08, has shown remarkable momentum with a 90% surge over the past six months according to InvestingPro data.
Yu also exercised options to acquire 30,000 shares of Disc Medicine common stock at a price of $2.65, for a total value of $79,500. This represents a significant discount to the current market value, with the stock trading at a Price-to-Book ratio of 5.73.
Following these transactions, Yu directly owns 40,555 shares of Disc Medicine. The $3.3 billion market cap company maintains strong liquidity with a current ratio of 23.45 and more cash than debt on its balance sheet. InvestingPro analysis reveals several more insights about IRON’s financial health and growth prospects, available through their comprehensive Pro Research Reports covering 1,400+ top US stocks.
In other recent news, Disc Medicine announced the pricing of its upsized public offering, valued at approximately $250 million, involving the sale of 2,619,049 shares of common stock and pre-funded warrants. This announcement follows the company’s earlier launch of a $220 million stock offering, aimed at supporting the commercialization of bitopertin and funding research and development. Additionally, Disc Medicine submitted a New Drug Application for bitopertin in erythropoietic protoporphyria, receiving a priority review from the FDA, which could expedite approval by late 2025 or early 2026. Raymond James reiterated its Strong Buy rating for Disc Medicine, highlighting the potential of DISC-0974 as a significant growth driver. The firm projects DISC-0974 sales in anemia of myelofibrosis to reach approximately $400 million by 2035, with a potential launch in 2028. Furthermore, Disc Medicine plans to present initial data from its RALLY-MF Phase 2 trial of DISC-0974 at the upcoming American Society of Hematology Annual Meeting. The trial evaluates DISC-0974 as a monotherapy and in combination with JAK inhibitors. These developments reflect Disc Medicine’s ongoing efforts in advancing its pipeline and securing financial resources for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.